1. Home
  2. LAW vs MYGN Comparison

LAW vs MYGN Comparison

Compare LAW & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

N/A

Current Price

$4.44

Market Cap

466.2M

Sector

Technology

ML Signal

N/A

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

N/A

Current Price

$4.85

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LAW
MYGN
Founded
2013
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
466.2M
481.6M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
LAW
MYGN
Price
$4.44
$4.85
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$8.00
$7.64
AVG Volume (30 Days)
597.5K
1.5M
Earning Date
05-25-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
22.58
N/A
EPS
N/A
N/A
Revenue
$156,849,000.00
$771,400,000.00
Revenue This Year
$11.23
$7.19
Revenue Next Year
$10.60
$5.64
P/E Ratio
N/A
N/A
Revenue Growth
8.29
2.33
52 Week Low
$2.45
$3.76
52 Week High
$9.11
$10.32

Technical Indicators

Market Signals
Indicator
LAW
MYGN
Relative Strength Index (RSI) 51.08 45.81
Support Level $3.92 $3.93
Resistance Level $4.81 $5.63
Average True Range (ATR) 0.40 0.41
MACD 0.23 0.07
Stochastic Oscillator 78.72 48.76

Price Performance

Historical Comparison
LAW
MYGN

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: